SynAct Pharma AB (8F8) Stock Price & Analysis
8F8 Stock Chart & Stats
- Day’s Range
- EUR 1.45 - EUR 1.49
- 52-Week Range
- EUR 0.97 - EUR 2.24
- Previous Close
- EUR 1.53
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 83.18M
- Enterprise Value
- EUR 1.17B
- Total Cash (Recent Filing)
- EUR 14.23M
- Total Debt (Recent Filing)
- EUR 929.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.46
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage gives SynAct greater financial flexibility than a highly debt-funded biotech. The company is less exposed to interest costs and refinancing pressure, preserving more ability to direct available capital toward clinical development and pipeline advancement.
Differentiated Therapeutic Approach
The focus on resolving inflammation without broadly suppressing immune function provides a differentiated clinical rationale within inflammatory and autoimmune diseases. If supported by trials, this mechanism could improve treatment positioning and create partnering interest.
Loss Improvement Versus 2023
Although SynAct remains loss-making, the substantial reduction in net loss from 2023 indicates that reported losses have not followed a continuously worsening path. Continued cost discipline could preserve capital while the company advances its clinical pipeline toward monetization.
Bears Say
No Commercial Revenue
The absence of commercial revenue means SynAct has no recurring operating income to fund research, trials, or corporate costs. Its medium-term financial outlook therefore remains dependent on clinical progress and future financing, licensing, or commercialization success.
Sustained Cash Burn
Persistent negative operating and free cash flow shows that the current business consumes substantial capital rather than generating it. Unless spending converts into clinical or partnering milestones, continued external funding could constrain strategy and increase dilution risk.
Uneven Loss Trajectory
The reversal after earlier loss improvement indicates that cost and earnings performance remain uneven. This makes the path to financial sustainability less predictable and suggests that operational spending may continue to fluctuate before any commercial revenue base emerges.
SynAct Pharma AB News
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
SynAct Pharma AB ( ($SE:SYNACT) ) just unveiled an update. SynAct Pharma has released further analysis from its Phase 2b ADVANCE study of resomelagon in treatment-naïve rheumatoid arthritis patients, reinforcing
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
SynAct Pharma AB ( ($SE:SYNACT) ) has issued an announcement. SynAct Pharma has signed a term sheet with Brazilian drug maker Hipolabor Farmacêutica for a co-development and commercialization partnership around
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
What is SynAct Pharma AB’s market cap?
When is SynAct Pharma AB’s upcoming earnings report date?
How were SynAct Pharma AB’s earnings last quarter?
Is SynAct Pharma AB overvalued?
Does SynAct Pharma AB pay dividends?
What is SynAct Pharma AB’s EPS estimate?
How many shares outstanding does SynAct Pharma AB have?
What happened to SynAct Pharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SynAct Pharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeppe Ovli Ovlesen
- Employees
- 8
- Website
- www.synactpharma.com
- Address
- Scheelevägen 2, Lund, SN, 223 63, SE
SynAct Pharma AB (8F8) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |
